

( (S (NP-SBJ-1 (NP A new drug)
               (SBAR (WHNP-2 0)
		     (S (NP-SBJ *T*-2)
			(VP to
			    (VP prevent
				(NP (NP the rejection)
				    (PP of
					(NP transplanted organs))))))))
     (VP has
         (VP been
             (VP (ADVP-MNR successfully)
                 used
                 (NP *-1)
                 (PP-CLR on
			 (NP (QP more than 100)
			     patients))
		 (PP-LOC at
			 (NP (NP the University)
			     (PP of
				 (NP Pittsburgh))))
		 ,
		 (PP according
		     (PP to
			 (NP researchers))))))
     .))
( (S (S (NP-SBJ-1 (NP The drug)
                  ,
                  (SBAR (WHNP-2 which)
                        (S (NP-SBJ *T*-2)
                           (VP is
                               (ADVP-TMP still)
                               (PP-LOC-PRD in
					   (NP the experimental phase)))))
                  ,)
        (VP has n't
            (VP been
                (VP approved
                    (NP *-1)
                    (ADVP-TMP yet)
                    (PP by
                        (NP-LGS the Food and Drug Admistration))))))
     , 
     and
     (S (NP-SBJ its long-term effects)
        (VP are
            (ADJP-PRD unknown)))
     .))
( (S But
     (NP-SBJ researchers)
     (VP say
         (SBAR 0
               (S (NP-SBJ (NP the drug)
                          ,
                          (VP called
                              (S (NP-SBJ *)
				 (NP-PRD FK-506)))
                          ,)
                  (VP could
                      (VP revolutionize
                          (NP the transplantation field)
                          (PP-MNR (PP by
				      (S-NOM (NP-SBJ *)
					     (VP reducing
						 (NP harmful side effects))))
				  and
				  (PP by
				      (S-NOM (NP-SBJ *)
					     (VP lowering
						 (NP rejection rates))))))))))
     .))
( (S (NP-SBJ Rejection)
     (VP has
         (VP been
             (NP-PRD the major obstacle)
	     (PP-LOC in
		     (NP (NP the (QP approximately 30,000) organ transplants)
			 (VP performed
			     (NP *)
			     (ADVP-LOC world-wide)
			     (NP-TMP each year))))))
     .))
( (S (NP-SBJ-2 Researchers)
     (VP began
         (S (NP-SBJ *-2)
            (VP using
                (NP the drug)
		(PP-CLR *ICH*-3)))
	 (PP-TMP in
		 (NP February))
	 (PP-CLR-3 on
		   (NP (NP patients)
		       (SBAR (WHNP-1 who)
			     (S (NP-SBJ *T*-1)
				(VP had
				    (VP received
					(NP kidney , liver , heart and pancreas 
					    transplants))))))))
     .))
( (S (NP-SBJ-1 (QP Only two of 111)
	       transplants)
     (VP have
         (VP been
             (VP rejected
                 (NP *-1))))
     .))
( (S (NP-SBJ-1 (NP The drug)
               ,
               (VP discovered
                   (NP *)
                   (PP-TMP in
			   (NP 1984)))
               ,)
     (VP is
         (VP metabolized
             (NP *-1)
             (PP-CLR from
		     (NP (NP soil fungus)
			 (VP found
			     (NP *)
			     (PP-TMP in
				     (NP Japan)))))))
     .))
( (S (NP-SBJ The Pittsburgh patients)
     (VP are
         (NP-PRD (NP the first humans)
                 (SBAR (WHNP-4 0)
		       (S (NP-SBJ-1 *T*-4)
			  (VP to
			      (VP be
				  (VP given
				      (NP *-1)
				      (NP (NP the drug)
					  ,
					  (SBAR (WHNP-3 which)
						(S (NP-SBJ-2 *T*-3)
						   (VP is
						       (VP made
							   (NP *-2)
							   (PP by
							       (NP-LGS Fujisawa Pharmaceutical Co))))))))))))))
     .))
( (SINV ``
	(S-TPC-1 (NP-SBJ We)
		 (VP 're
		     (VP shocked
			 (PP by
			     (NP it))))
		 ,
		 (SBAR because
		       (S (NP-SBJ it)
			  (VP 's
			      (VP worked
				  (ADVP so fast))))))
	, 
	''
	(VP said
	    (S *T*-1))
	(NP-SBJ (NP Dr. Thomas E. Starzl)
		,
		(NP (NP director)
		    (PP of
			(NP the
			    (NAC University
				 (PP of
				     (NP Pittsburgh)))
			    Transplantation Program)))
		,)
	(PP-LOC at
		(NP a news conference))
	(ADVP-LOC here)
	(NP-TMP yesterday)
	.))
( (SINV ``
	(S-TPC-1 (NP-SBJ We)
		 (VP consider
		     (S (NP-SBJ it)
			(NP-PRD (NP a life-saving drug)
				,
				(PP like
				    (NP (NP one)
					(PP for
					    (NP AIDS))))))))
	, 
	''
	(VP said
	    (S *T*-1))
	(NP-SBJ (NP Dr. John Fung)
		,
		(NP (NP an immunologist)
		    (PP-LOC at
			    (NP (NP the University)
				(PP of
				    (NP Pittsburgh))))))
	.))
( (S (NP-SBJ Researchers)
     (VP say
         (SBAR 0
               (S (NP-SBJ they)
                  (VP believe
                      (SBAR 0
                            (S (NP-SBJ FK-506)
                               (VP is
                                   (ADJP-PRD (ADJP (QP 100 times)
						   more effective)
                                             (PP than
                                                 (NP (NP the traditional anti-rejection drug)
                                                     ,
                                                     (NP cyclosporine)
						     ,
						     (VP made
							 (NP *)
							 (PP by
							     (NP-LGS Swiss pharmaceutical giant
								     Sandoz Ltd)))))))))))))
     .))
( (S (NP-SBJ-1 They)
     (VP are
         (ADVP also)
         (VP encouraged
	     (NP *-1)
             (PP by
                 (NP-LGS (NP the (ADJP relatively mild) side effects)
			 (PP of
			     (NP FK-506))
			 ,
			 (PP compared
			     (PP with
				 (NP (NP cyclosporine)
				     ,
				     (SBAR (WHNP-507 which)
					   (S (NP-SBJ *T*-507)
					      (VP can
						  (VP cause
						      (NP (NP renal failure)
							  ,
							  (NP morbidity)
							  ,
							  (NP nausea)
							  and
							  (NP other problems)))))))))))))
     .))
( (S ``
     (S-1 (NP-SBJ (NP The side effects)
		  (PRN -LCB-
		       (PP of
			   (NP cyclosporine))
		       -RCB-))
	  (VP have
	      (VP made
		  (S (NP-SBJ (NP the penalty)
			     (PP for
				 (NP its success)))
		     (ADJP-PRD rather high)))))
     , 
     ''
     (NP-SBJ Dr. Starzl)
     (VP said
	 (S *T*-1))
     .))
( (S (NP-SBJ Dr. Fung)
     (VP said
         (SBAR (SBAR that
                     (S (NP-SBJ FK-506)
                        (VP would not
                            (VP be
                                (ADJP-PRD available)
				(PP-LOC in
					(NP the market))
				(PP-TMP for
					(NP (QP at least a) year))))))
               , 
	       and
               (SBAR that
                     (S (NP-SBJ the FDA approval process)
                        (ADVP-TMP usually)
			(VP takes
                            (NP (NP three years)
                                to
				(NP five years)))))))
     .))
( (S (NP-SBJ There) 
     (VP are
         (NP-PRD no firm plans
                 (S (NP-SBJ *)
                    (VP to
                        (VP expand
                            (NP the experimental program)
                            (PP-DIR-CLR beyond
					(NP (NP (NP the University)
						(PP of
						    (NP Pittsburgh)))
					    ,
					    (SBAR (WHNP-1 whose hospital)
						  (S (NP-SBJ *T*-1)
						     (VP performs
							 (NP (NP the most transplants)
							     (PP-LOC in 
								     (NP the world)))))))))))))
     .))
( (S (S (NP-SBJ Researchers)
        (VP could n't
            (VP estimate
                (NP (NP the cost)
		    (PP of
			(NP the drug))
		    (SBAR (WHADVP-1 when)
			  (S (NP-SBJ it)
			     (VP reaches
				 (NP the market)
				 (ADVP-TMP *T*-1))))))))
     , 
     but
     (S (NP-SBJ they)
        (VP said
            (SBAR 0
                  (S (NP-SBJ FK-506)
                     (VP will
                         (VP (VP enable
                                 (S (NP-SBJ patients)
                                    (VP to
                                        (VP cut
                                            (NP hospital stays)
                                            (PP-EXT by
						    (NP 50 %))))))
                             and
                             (VP reduce
                                 (NP (NP the number)
                                     (PP of
                                         (NP (NP blood tests)
                                             (VP used
                                                 (S-CLR (NP-SBJ *)
							(VP to
							    (VP monitor
								(NP (NP the dosage)
								    (PP of
									(NP (NP cyclosporine)
									    and 
									    (NP other drugs)))))))
						 (PP-LOC among
							 (NP transplant recipients)))))))))))))
     .))
( (S (NP-SBJ Dr. Starzl)
     (VP said
         (SBAR (SBAR 0
                     (S (NP-SBJ-1 the research)
                        (VP has
                            (VP been
                                (ADVP largely)
				(VP financed
                                    (NP *-1)
                                    (PP (PP by
                                            (NP-LGS (NP the National Institute)
						    (PP of
							(NP Health))))
                                        and
                                        (PP by
                                            (NP-LGS university funds))))))))
               ,
	       and
               (SBAR that
                     (S (NP-SBJ Fujisawa)
                        (VP did n't
                            (VP give
                                (NP the hospital)
                                (NP any grants)))))))
     .))
( (S (NP-SBJ He)
     (VP said
         (SBAR that
               (S (NP-SBJ the research team)
                  (VP had
                      (NP (NP no financial stake)
                          (PP-LOC in
				  (NP the drug)))))))
     .))
( (S ``
     (S-TPC-2 (S (NP-SBJ We)
		 (VP 've
		     (VP known
			 (PP-TMP for
				 (NP six months))
			 (NP (NP the effect)
			     (PP of
				 (NP this drug))))))
	      , 
	      and
	      (S (NP-SBJ (NP our advice)
			 (PP to
			     (NP our people)))
		 (VP has
		     (VP been
			 (S-PRD (NP-SBJ *)
				not
				(VP to
				    (VP buy
					(NP (NP the company 's)
					    stock))))))))
     , 
     ''
     (NP-SBJ-1 Dr. Starzl)
     (VP said
	 (S *T*-2)
	 ,
	 (S-ADV (NP-SBJ *-1)
		(VP adding
		    (SBAR that
			  (S (S-NOM-SBJ (NP-SBJ *)
					(VP profiting
					    (PP-CLR from
						    (NP FK-506))))
			     (VP would n't
				 (VP be
				     (ADJP-PRD ethical))))))))
     .))
